Envafolimab

Envafolimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD274, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Envafolimab (KN035) is the world's first new fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc. Compared with the PD-1/PD-L1 antibodies currently on the market and under development, it has a distinct advantage. Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and fast tumor penetration, which can improve the compliance of tumor patients and improve the quality of life of patients, which is in line with the future trend of long-term management of tumors as chronic diseases.

0.01 M PBS. pH 7.4.

Recombinant

Purified from cell culture supernatants by Protein A/G chromatography.